0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-23R

IL-23R

Brief Information

Name:Interleukin 23 Receptor
Target Synonym:IL-23 receptor,IL23R,Interleukin 23 Receptor,Interleukin-23 Receptor,IL-23R
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ILR-H5254-SPR
 IL-23R SPR

Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL23A & IL12B, His Tag (Cat. No. ILB-H52W5)with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

ILR-H52H4-SPR
 IL-23R SPR

Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) captured on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (SPR verified) (Cat. No. ILR-H52H4) with an affinity constant of 3.39 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

IL-23 R,IL-23 Receptor

Background

Interleukin 23 receptor (IL-23R) is a type I cytokine receptor, and IL-23R pairs with the receptor molecule IL12RB1/IL12Rbeta1, and both are required for IL23A signaling. Also, IL-23R associates constitutively with Janus kinase 2 (JAK2), and binds to transcription activator STAT3 in a ligand-dependent manner. Furthermore, IL-23R mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. As for IL-23, it may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PN-235 JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC Phase 3 Clinical Protagonist Therapeutics Inc Psoriasis; Colitis, Ulcerative; Plaque psoriasis Details
PN-232 PN-232; JNJ75105186 Phase 1 Clinical Protagonist Therapeutics Inc Details
PN-235 JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC Phase 3 Clinical Protagonist Therapeutics Inc Psoriasis; Colitis, Ulcerative; Plaque psoriasis Details
PN-232 PN-232; JNJ75105186 Phase 1 Clinical Protagonist Therapeutics Inc Details

This web search service is supported by Google Inc.

totop

Laisser un message